A Study of SPG Block for Opioid Withdrawal

Completed · Not applicable

Conditions studied: Opioid Use Disorder

In brief

Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. This study is a pilot study investigating whether blocking the SPG helps reduce withdrawal symptoms in OUD. This study does not involve treatment or induction onto medications. It is a proof of principal study only. We will recruit non-treatment seeking subjects with OUD who are admitted to the research unit for all procedures.

Key facts

Study ID

NCT04946656

Run by

New York State Psychiatric Institute

People needed

3

Starts

2023-02-03

Expected to finish

2025-09-03

Last updated by the study team

2025-10-30

Who can join

Age: 22 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Opioid Use Disorder, moderate to severe
• Ages 22 to 50
• Lives in New York City, able to travel for visits
• Willing to be admitted to an inpatient unit

You may not qualify if…

• Medical disorder, for who study participation could be deleterious (neurologic, cardiac, renal or infectious disease
• Hypertension: BP > 150/100
• Elevated liver function tests (AST, ALT) > 3x normal
• Having a painful medical illness for which opioids are needed (including upcoming surgery).

Where it is running

• 1051 Riverside Drive — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.